NoRo pilots the country’s first and only patient-run reference center for rare diseases
Article
In 2007, Dorica Dan, the mother of a child with the rare disease Prader Willi Syndrome, envisioned the first and only patient-run reference center for rare diseases in Europe. It would help patients and families with the decisions and therapies that are needed after receiving their diagnosis.
Materials innovation company Checkerspot is using microalgae to create a sustainable alternative to petroleum
Article
Molecular biologist Scott Franklin has spent the last 25 years in awe of the secret properties of microalgae—what he calls “the mother of all higher plants.” While many people consider it an environmental scourge—certain species have the power to proliferate into a toxic bloom within hours—microalgae is, for Franklin, a wondrous source of triglyceride oils and fatty acids. “There are thousands of strains of microalgae everywhere, but you don’t see them,” he says. “There’s a huge diversity out there.”
Through an organization called ASrid, patient families find connection and hope
Article
Ahead of Rare Disease Day, Illumina is recognizing four rare disease patient organizations around the world. ASrid is the third in our series this month.
The kids in Kanade Kawagoe’s elementary school class were excited to see a Polaroid camera for the first time. “The children, who are used to being photographed with their cell phone cameras, waited with sparkling eyes for the photos to come out of the camera,” says Naomi Kawagoe, Kanade’s mother. “The sight of these children was awe-inspiring.” The Kawagoes were photographing a day in the life of rare disease.
On National Inventors Day, two employees talk about getting “hooked” on sequencing and the importance of being wrong (sometimes)
Article
As a global leader in DNA sequencing and array-based technologies, Illumina is continuously striving to improve human health by unlocking the power of the genome. That means focusing on innovation—constant innovation. In 2021, Illumina employees filed a record 171 new patent applications—a 69 percent increase over the previous year.
As part of the support, Illumina pledged $20 million over four years to help strengthen sequencing technology for 20 African countries. This in-kind donation includes next-generation sequencing platforms, reagents and training support.
Today, the Montreal Neurological Institute-Hospital at McGill University (The Neuro) announced a new research collaboration with Illumina, along with Takeda Development Center Americas, Inc., and pharmaceutical powerhouse Roche. Driven by the power of Illumina’s WGS capability, the partnership will create a powerful drug discovery platform for neurological conditions such as Parkinson’s disease and REM sleep behavior disorders.
AJ Patel had six months to live. Eight years later, he tells us how biomarker testing changed everything.
Article
Eight years ago, AJ Patel was diagnosed with advanced lung cancer. The Southern California resident and father of three had tumor masses in both lungs. AJ’s doctor told him that if he didn’t do anything, he would have just six months to live. But fortunately, AJ met a physician who recommended he ask about biomarker testing, an approach that uses next-generation sequencing to determine an individual’s cancer-causing genes and other markers.
Joint study will assess clinical value of comprehensive genomic profiling (CGP) on cancer therapy options in patients with advanced disease
Press Release
SAN DIEGO, February 7, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN), today announced an agreement with the Jean Perrin Center at the Clermont-Ferrand University Hospital in France to assess the clinical value of comprehensive genomic profiling (CGP) in cancer therapy options in patients with late-stage disease compared to use of current standard of care, including small panel tests.
